Asunto(s)
Citocinas/sangre , Sífilis/inmunología , Células TH1/metabolismo , Células Th17/metabolismo , Células Th2/metabolismo , Adulto , Análisis de Varianza , Femenino , Humanos , Interferón gamma/sangre , Masculino , Sífilis/microbiología , Treponema pallidum , Factor de Necrosis Tumoral alfa/sangreAsunto(s)
Infecciones por Herpesviridae/prevención & control , Herpesvirus Humano 8/genética , Péptidos/genética , Saliva/virología , Sarcoma de Kaposi/prevención & control , Línea Celular , Clonación Molecular , Infecciones por Herpesviridae/transmisión , Infecciones por Herpesviridae/virología , Humanos , Sarcoma de Kaposi/virologíaAsunto(s)
Síndrome Antifosfolípido/inmunología , Inmunoterapia/efectos adversos , Melanoma/terapia , Piel/inmunología , Anticoagulantes/uso terapéutico , Antineoplásicos/efectos adversos , Síndrome Antifosfolípido/tratamiento farmacológico , Síndrome Antifosfolípido/patología , Biopsia , Bloqueadores de los Canales de Calcio/uso terapéutico , Células Dendríticas/inmunología , Células Dendríticas/trasplante , Quimioterapia Combinada , Mano , Humanos , Interferón alfa-2 , Interferón-alfa/efectos adversos , Metástasis Linfática , Masculino , Melanoma/inmunología , Melanoma/secundario , Persona de Mediana Edad , Necrosis , Polietilenglicoles/efectos adversos , Proteínas Recombinantes , Piel/patología , Dedos del Pie , Resultado del TratamientoRESUMEN
BACKGROUND: Specific cutaneous lesions of Waldenström macroglobulinemia are rare and include neoplastic cell infiltrates, IgM bullous disease, and so-called IgM-storage papules, which characterize cutaneous macroglobulinosis (CM). OBSERVATIONS: We report 2 patients with CM. In patient 1, CM started as small papules, as reported in most of the previously published case studies of CM. In patient 2, lesion evolution was remarkable by its severity, with large ulcerated nodules, and the disease progressed rapidly. As mentioned for half the previously described patients, peripheral neuropathy was suspected in patient 2 and demonstrated in patient 1, with production of antibodies to myelin-associated glycoprotein. CONCLUSIONS: To the best of our knowledge, rituximab treatment of Waldenström macroglobulinemia associated with CM has not been described previously. Rituximab caused complete remission of the lesions in patient 1, whereas disease rapidly progressed in patient 2, and the patient died. These observations suggest that evolution of the cutaneous IgM-storage lesions reflects that of the underlying Waldenström macroglobulinemia, and CM is not a prognostic marker.